115833-93-7

Basic information

• Product Name: 3-PYRROLIDIN-1-YL-PHENYLAMINE
• Synonyms: 3-PYRROLIDIN-1-YL-PHENYLAMINE;3-PYRROLIDIN-1-YLANILINE;AKOS BB-8949;TIMTEC-BB SBB010438;3-(Pyrrolidin-1-yl)aniline 97%;1-(3-Aminophenyl)pyrrolidine;3-(Pyrrolidin-1-yl)aniline97%;Benzenamine, 3-(1-pyrrolidinyl)-
• CAS NO: 115833-93-7
• Molecular Formula: C₁₀H₁₄N₂
• Molecular Weight: 162.23
• Product Categories: Amines;Phenyls & Phenyl-Het;Phenyls & Phenyl-Het
• Mol File: 115833-93-7.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 332.6 °C at 760 mmHg
• Flash Point: 132.1 °C
• Appearance: /
• Density: 1.109 g/cm³
• Vapor Pressure: 0.000144mmHg at 25°C
• Refractive Index: 1.609
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 3-PYRROLIDIN-1-YL-PHENYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-PYRROLIDIN-1-YL-PHENYLAMINE(115833-93-7)
• EPA Substance Registry System: 3-PYRROLIDIN-1-YL-PHENYLAMINE(115833-93-7)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 115833-93-7(Hazardous Substances Data)

Usage

General Description

3-Pyrrolidin-1-yl-phenylamine, also known as PPAP, is a chemical compound with potential psychoactive effects. It is a derivative of phenylalanine and acts as a selective dopamine reuptake inhibitor, increasing the levels of dopamine in the brain. PPAP has been studied for its potential use as a nootropic and antidepressant. It is also known to have stimulant effects and has been investigated for its potential as a performance-enhancing drug. However, the potential risks and side effects of PPAP are not well understood, and its use is not approved for medical or recreational purposes. Its classification as a controlled substance varies by country.

InChI:InChI=1/C10H14N2/c11-9-4-3-5-10(8-9)12-6-1-2-7-12/h3-5,8H,1-2,6-7,11H2

Upstream product

• 132993-20-5 N-(3-nitrophenyl)tetrahydropyrrole 
• 123-75-1 pyrrolidine 
• 591-19-5 m-Bromoaniline 
• 626-01-7 3-Iodoaniline 
• 1258532-12-5 C₁₅H₂₂N₂O₂ 
• 99-09-2 3-nitro-aniline 
• 109-99-9 tetrahydrofuran 
• 108-45-2 m-phenylenediamine 

Downstream Products

• 168162-35-4 1-(3-Isocyanato-phenyl)-pyrrolidine 
• 1092504-37-4 C₃₃H₃₈Cl₂N₆O₂ 
• 1002158-45-3 N-(4-((3-(pyrrolidin-1-yl)phenylamino)methyl)benzyl)pyrimidin-2-amine 
• 84995-54-0 N-methyl-3-(pyrrolidin-1-yl)aniline 
• 1092504-36-3 C₃₄H₄₀Cl₂N₆O₂ 
• 1092504-38-5 C₂₉H₃₀Cl₂N₄O₂ 
• 1092504-65-8 C₂₁H₂₆N₄O 
• 1392494-13-1 2-phenyl-N-(3-(pyrrolidin-1-yl)phenyl)butanamide 
• 1392494-15-3 2-(3-chlorophenyl)-N-(3-(pyrrolidin-1-yl)phenyl)acetamide 
• 1234371-17-5 1-(2-amino-4-pyrrolidin-1-ylphenyl)-1-(1,3-benzothiazol-2-yl)-2,2,2-trifluoroethanol 
• 1092504-64-7 C₂₈H₃₂N₄O 
• 1062073-58-8 C₂₄H₂₂ClN₃O 
• 677276-49-2 2-(chloroethoxy)-N-(3-pyrrolidine-1-ylphenyl)-carboxamide 
• 1055988-24-3 C₁₈H₁₉N₃O₃ 

Relevant articles and documents

1,3-Aza-Brook Rearrangement of Aniline Derivatives: In Situ Generation of 3-Aminoaryne via 1,3-C-(sp2)-to-N Silyl Migration

The design, synthesis, and validation of 3-aminobenzyne precursors induced by C-(sp2)-to-N 1,3-aza-Brook rearrangement have been achieved, allowing access to diverse aniline derivatives. Through crossover experiments, we demonstrated the intramolecular mechanism of 1,3-C-to-N silyl transfer. To gain insight into the regioselectivity observed in the reactions, we performed density functional theory calculations. Finally, the method was applied to the synthesis of xylanigripones A in five linear steps in an overall yield of 30%.

Squarylium compound

PROBLEM TO BE SOLVED: To provide a squarylium compound excellent in stability in a polar solvent, a solution containing the same and a resin composition. SOLUTION: There is provided a squarylium compound represented by the following formula (1), where Rs

Dipyrimidine amines: A novel class of chemokine receptor type 4 antagonists with high specificity

The C-X-C chemokine receptor type 4 (CXCR4)/stromal cell derived factor-1 (SDF-1 or CXCL12) interaction and the resulting cell signaling cascade play a key role in metastasis and inflammation. On the basis of the previously published CXCR4 antagonist 5 (WZ811), a series of novel nonpeptidic anti-CXCR4 small molecules have been designed and synthesized to improve potency. Following a structure-activity profile around 5, more advanced compounds in the N,N-(1, 4-phenylenebis(methylene)) dipyrimidin-2-amines series were discovered and shown to possess higher CXCR4 binding potential and specificity than 5. Compound 26 (508MCl) is the lead compound and exhibits subnanomolar potency in three in vitro assays including competitive binding, Matrigel invasion and Gαi cyclic adenosine monophosphate (cAMP) modulation signaling. Furthermore, compound 26 displays promising effects by interfering with CXCR4 function in three mouse models: paw inflammation, Matrigel plug angiogenesis, and uveal melanoma micrometastasis. These data demonstrate that dipyrimidine amines are unique CXCR4 antagonists with high potency and specificity.